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Cigarette smoking is associated with an increased risk ofleukemia; beniene, an established leuke-
mogen, is present in cigarette smoke. By combining epidemiologic data on the health effects of
smokingwith riskassessment techniques for low-doseexrapolation, we assessed the proportion of
smoking-induced totalleukemia and acute myeloid leukemia (AML) attributable to the benzene in
cigarette smoke. We fit both linear andquadratic models to data from two benzene-exposed occu-
pational cohorts to estimate the leukemogenic potency ofbenzene. Using multiple-decrement life
tables, we calculated lifetime risks of total leukemia and AML deaths for never, light, and heavy
smokers. We repeated these calculations, removingtheeffict ofbenzene incigarettes based on the
estimated potencies. From these life tables we determined smoking-attributable risks and benzene-
attributable risks. The ratio ofthe latter to the former constitutes the proportion of smoking-
induced cases attributable to benzene. Based on linear potency models, the benzene in cigarette
smoke contributed from 8 to 48% ofsmoking-induced total leukemia deaths [95% upper confi-
dence limit (UCL), 20-66%], and from 12 to 58% ofsmoking-induced AML deaths (95% UCL,
19-121%). The indCusion of a quadratic term yielded results that were comparable; however,
potencymodelswithonlyquadratic terms resulted in muchlowerattibutablefractions-all c 1%.
Thus, benzene is estmated to be responsible forapproximately one-tenth to one-halfofsmoking-
induced totl leukenmia mortalityand up to three-fifths ofsmoking-relatedAMLmortality. In con-
trast to theoretical arguments that linear models substantially overestimate low-dose risk, linear
extrapolations fromempirical dataover adoserangeof10- to 100-fold resultedin plausiblepredic-
tions. Key work benzene, environmental exposure, epidemiology, leukemia, life tables, occupa-
tional exposure, riskassessment, smoking. Environ Healbh Perect 108:333-339 (2000). [Online
23 February2000]
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Based on the results of several large cohort
studies (1-3), cigarette smoking is associated
with an increased risk ofleukemia. The rela-
tive risks (RRs) range from 1.5 to 2.0.
Although cigarette smoke contains a multi-
tude of toxic chemical compounds,
researchers have not yet established which
chemicals are responsible for the leuke-
mogenicityofthis complex mixture.
Benzene is present in mainstream
cigarette smoke at concentrations ofapproxi-
mately 45 pg/cigarette, and in sidestream
smoke at concentrations about 10 times
higher. Personal exposure assessment
research has indicated that the average ciga-
rette smoker inhales 6-10 times the benzene
inhaled by the average nonsmoker, and that
approximately 90% of a smoker's benzene
exposure is fromsmoking (4). For nonsmok-
ers, most benzene exposure comes from
automobile exhaust, environmental tobacco
smoke, and exposure to consumer products
(5). Benzene induces leukemia both in
humans with occupational exposures (6,7)
and in experimental animals (8,9). Some
research indicates the strongest association of
benzene to be with acute myeloid leukemia
(AML) (10,11), but effects on other types of
leukemia have not been ruled out (12). The
purpose of this investigation was to deter-
mine what proportion ofsmoking-induced
leukemia is likely to be caused by the
benzene in cigarette smoke.
Several regulatory agencies, including the
U.S. Environmental Protection Agency
(EPA), have established procedures for esti-
mating risks from low- or moderate-level
chemical exposures (13). These risk assess-
ment methods, which assume low-dose lin-
earity, have been used for over a decade to
set regulatory standards, and we used these
methods to calculate leukemia risks from
benzene in cigarette smoke. The EPA has
proposed new guidelines for risk assessment
(14), which are still under debate. Our use
of the earlier standard permitted an assess-
ment of its adequacy for benzene. Some
authors have argued that the true low-dose
relationship for this compound is sublinear,
and that the default assumptions will there-
fore result in a substantial overestimation of
benzene's potency (15). This investigation
was specifically designed to quantitatively test
whether these assumptions do, in fact, result
in the prediction of more leukemia deaths
than actually occur in smokers.
In general, risk assessment uses quantita-
tive dose-response data that associate a
chemical exposure with the risk of cancer
mortality to obtain a potency, and low-dose
extrapolation models to estimate the risk at
lower doses. Often the dose levels ofinterest
are experienced through environmental
exposure in the general population or
through occupational exposure in groups of
workers. In this case, we examined the ben-
zene doses inhaled by smokers. Unlike many
exposure scenarios, the risks to smokers have
been well characterized. Thus, the predicted
leukemia risks attributable to low-doses of
benzene can be compared with the actual
leukemia risk observed in epidemiologic
studies ofsmoking.
Materials and Methods
We used five steps to estimate the proportion
ofsmoking-induced leukemia caused by ben-
zene in cigarette smoke: a) a calculation of
the lifetime risk ofleukemia due to smoking;
b) a determination of the leukemogenic
potency of benzene; c) the quantification of
benzene dose for smokers at two levels of
smoking; a) the characterization of the low-
dose risk ofleukemia due to the benzene in
cigarette smoke [using the results of b) and
c)]; and e) a comparison ofthe predicted life-
time leukemia risk due to benzene in ciga-
rette smoke [from A] to the observed lifetime
leukemia riskdue to smoking [from a)].
Lifetime risk ofleukemia due to smok-
ing. We constructed life tables to calculate
cumulative lifetime risks of dying from
leukemia, stratified by smoking status (never,
former, light, or heavy). Life tables were
truncated at 75 years ofage to avoid instabili-
ty in the oldest age groups. We conducted
this exercise first for all leukemia and then
repeated it for AML alone [some authors
argue thatAML has generallyshown stronger
associations with benzene exposure than
other leukemia types (10)]. We used the life
table results to calculate thesmoking-induced
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excess lifetime risk ofdeath (ELR) (16) from
leukemia for each smoking category as fol-
lows: ELRsmokn = (cumulative lifetime risk
among smokers~- (cumulative lifetime risk
among never-smokers).
We conducted life table analyses sepa-
rately for males and females; the data used to
construct the male cause-specific AML life
tables are shown in Table 1. The mortality
rates for 1990 were taken from U.S. vital sta-
tistics (17). Because age- and sex-specific
AML rates were not available, we used scal-
ing factors derived from the Surveillance,
Epidemiology, and End Results (SEER)
mortality data (18) to convert myeloid
leukemia death rates (17) to AML death
rates. In the life table calculations, we parti-
tioned age-specific leukemia and all-cause
death rates bysmoking status (never, former,
light, and heavy) using smoking prevalences
and smoking-related RRs. Partitioning for-
mulas have been published previously (19).
We calculated smoking prevalences from the
September 1989 Current Population Survey
dataset (20) (Table 2). Age-specific all-cause
mortality RRs (21) for former, light
(weighted average of 10-19 and 20-39 ciga-
rettes/day), and heavy (. 40 cigarettes/day)
smokers were taken from published studies:
for all leukemia combined, and for myeloid
leukemia alone, we used the Cancer
Prevention Studies I and II, respectively (2).
RRs for all leukemia in males were 1.36,
1.32, and 1.61 among former, light, and
heavy smokers, respectively; RRs for myeloid
leukemia in males were 1.17, 1.65, and 1.75.
Because age-specific RRs were not reported
and because RRs for females were unstable
as a result ofsparse data, RRs for males were
applied to both men and women and to all
age groups from 35 to 75 years ofage.
Potency caleulation. We obtained several
benzene potency estimates for acute nonlym-
phocytic (myeloid or monocytic) leukemia
and for all leukemia. These included potency
estimates published by Crump (22), whose
risk assessment ofbenzene-induced leukemia
was based on the Pliofilm cohort (23); esti-
mates that we calculated using summary
data from the analysis by Crump; and esti-
mates that we calculated using data from a
recently published studyofworkers in China
(24). Crump's analysis (22) of the Pliofilm
cohort included 1,717 white male workers
from Pliofilm manufacturing plants in
Akron, Ohio, and St. Mary's, Ohio. The
workers were considered to have no other
substantial workplace exposures; therefore,
the possibility of biased potency estimates
due to other leukemogens was small. The
cohort from China (24) was assembled from
672 factories in 12 cities, and included
74,828 exposed workers and 35,805 unex-
posed workers. Hayes et al. (24) did not
adjust for exposures to other chemicals,
although an examination ofprevious reports
reveals that most of the workers in China
were exposed to toluene and xylene in addi-
tion to benzene (25,26). Studies ofboth the
China cohort and the Pliofilm cohort
utilized exposure assessments that were based
on occupational histories, ambient benzene
expo-sure measurements, and detailed
production information.
The risk assessment of Crump (22)
updated a previous risk assessment (27) by
extending mortality data to the most recent
follow-up (28), and by expanding the analy-
ses to indude an exposure matrix developed
by Paustenbach et al. (29). Crump (22) pro-
vided sensitivity analyses of risk estimates
under various dose-response models for each
ofthe two exposure matrices, includinglinear
and nonlinear forms of both additive and
multiplicative risk models. We chose potency
estimates from linear multiplicative models
fit using the Paustenbach et al. (259 exposure
matrix, unweighted cumulative exposure,
and a 5-year lag.
We converted the potencies of Crump
(22) to per-cumulative-gram units to provide
compatibility with the units of exposure to
cigarette smoke-a nonoccupational but
chronic exposure.
1 ppm-year = (1/106) x (1 year)
x (250 workdays/year)
x (10 m3/workday)
x (1003 cm3/m3)
x (mL/cm3)
x (L/1,000 mL)
x (mol/24.45 L)
x (78.11 g benzene/mol)
= 7.987 g,
where workers are assumed to breathe 10
m3/workday, 24.45 Umol represents themolar
volume constant, and 78.11 g/mol is the
molecular weight ofbenzene. Accordingly, a
carcinogenic potency of 1 per ppm-year is
equivalent to 1 per 7.987 g, or 1.252 x 10-1
per cumulative gram benzene.
For our potency calculations based on
the Pliofilm data, we fit linear multiplicative
models ofthe form:
obs= ax exp(l +Pa , [1]
where obs = the number of deaths in the
specified exposure category, exp = the expect-
ed number of deaths based on the age and
sex distribution of the exposed group and
the death rates ofthe referent group, d= the
cumulative benzene dose in grams, P repre-
sents the leukemogenic potencyparameter of
benzene in per-cumulative-gram units, and
a represents the ratio of the background
leukemia risk in the industrial cohort to that
of the general population referent group
(e.g., the healthyworker effect). Crump (22)
did not make an adjustment for the healthy
worker effect in his final models. Equation 1
is a simplified version of the fundamental
relation between observed and expected
rates; Equation 1 is obtained by multiplying
both sides of this relation by the person-
years in the denominators ofboth rates. As is
standard practice for quantitative risk assess-
ment, we calculated a 95% upper confidence
limit (UCL) for each potency.
For the China data, we fit a linear model
without the a term because the analysis was
based on an internal comparison:
obs= exp(l + xa). [2]
Because the Pliofilm data suggest a non-
linear dose-response curve, we repeated the
Pliofilm analysis using two quadratic
multiplicative models:
obs=axexp(l +,Pxd2) [3]
obs=axexp(l+plxd+P2xd2). [4]
Table 1. Example oflife table data: male AML.
5-year
age
group
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
All-cause
death rate
per 100,000
1,135.2
25.6
31.6
127.2
166.3
184.9
223.4
280.7
344.2
491.1
756.5
1,208.5
1,902.7
2,847.6
4,345.4
Myeloid
leukemia
death rate
per 100,000
1.143
0.249
0.252
0.523
0.718
0.878
1.004
1.312
1.556
2.092
3.350
5.770
7.298
12.557
19.004
Age-
specific
scaling
factora
0.820
0.820
0.820
0.820
0.679
0.679
0.679
0.613
0.613
0.630
0.630
0.683
0.683
0.733
0.733
AML death
rate per
100,000b
0.937
0.204
0.206
0.429
0.488
0.596
0.682
0.804
0.953
1.317
2.109
3.940
4.983
9.202
13.926
All-cause RR
for smoking
Former Light Heavy
1 1 1
1 1 1
1 1 1
1 1 1
1 1 1
1 1 1
1 1 1
1.02 1.78 2.57
1.02 1.78 2.57
1.21 2.90 4.39
1.21 2.90 4.39
1.27 1.85 2.59
1.27 1.85 2.59
1.30 1.85 2.32
1.30 1.85 2.32
&Proportion ofmyeloid leukemias that are AML. bCalculated using scaling factor.
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In the Pliofilm data, neither of the two
leukemias in the lowest Paustenbach
exposure group were cell typed; therefore,
we present AML results under several
assumptions for this exposure category:
zero, one, or two deaths. For brevity, we
present results under the assumption ofone
AML death using linear (Equation 1) and
quadratic models (Equation 3), but only
partial results for zero and two AML deaths.
Data on mean exposures for each
category were available for the Pliofilm
cohort, but not for the cohort from China.
We therefore assigned the mid points for the
lower two categories (< 40 and 40-100
ppm-years) in this cohort, and avalue of130
ppm-years (1,038.31 cumulative grams) for
the open-ended category of> 100 ppm-years
(based on the lower limit plus one-half the
width ofthe next lower category).
Quantification ofbenzene dose in smok-
ers. The International Agency for Research
on Cancer (IARC) reported a range of
benzene values between 12 and 48 pg/ciga-
rette in mainstream smoke (30). Two stud-
ies (31,32) published since the IARC report,
both ofwhich used standard Federal Trade
Commission methods (33) and Kentucky
Reference filter cigarettes (1R4F; Tobacco
and Health Research Institute, University of
Kentucky, Lexington, KY), reported ben-
zene values of 45 and 51 pg/cigarette. One
of these studies (32) also tested a Kentucky
Reference nonfilter cigarette (1R1) and a
low-tar cigarette; benzene levels were 73
pg/cigarette in the nonfilter cigarette and 8
pg/cigarette in the low-tar cigarette.
Given this range and the documentation
of the smoking methods in the studies by
Byrd et al. (31) and Brunnerman et al. (32),
we selected 45 pg/cigarette as our estimate
of the benzene dose in mainstream smoke.
This estimate represents a reasonable aver-
age dose per cigarette across the lifetimes of
those persons represented in our life tables
(i.e., those who died in 1990).
Table 2. Age-specific smoking prevalences.
Prevalence ofsmoking
Age None Former Light Heavy
0 1 0 0 0
5 1 0 0 0
10 1 0 0 0
15 0.85 0.02 0.12 0.01
20 0.68 0.07 0.22 0.03
25 0.57 0.11 0.27 0.05
30 0.50 0.17 0.25 0.07
35 0.43 0.23 0.24 0.09
40 0.39 0.27 0.23 0.11
45 0.33 0.33 0.21 0.12
50 0.31 0.36 0.22 0.11
55 0.30 0.39 0.21 0.01
60 0.28 0.45 0.19 0.07
65 0.28 0.51 0.15 0.05
70 0.30 0.54 0.13 0.03
It is more difficult to choose an estimate
of the amount of benzene in sidestream
smoke because measurement methods are
not standardized. Given the uncertainty, we
chose 500 pg/cigarette, the mid point ofthe
range (300-700 pg/cigarette) reported by
Guerin et al. (33).
We assumed that 100% of the benzene
in mainstream smoke is inhaled. We
searched the literature but were unable to
find direct data on the proportion of side-
stream smoke inhaled by a smoker. We
therefore used data on the proportion of
nicotine inhaled from sidestream smoke. We
calculated that if each cigarette requires 10
min to smoke and generates an environmen-
tal nicotine concentration of 1,000 pg/m3
for the smoker [the maximum reported by
the National Research Council (34)], then
that smoker breathes, at most, 100 pg
sidestream nicotine from each cigarette:
1,000 pg/m3 x 1 m3/1,000 L
x 10 L breathed/min
x 10 min/cigarette
= 100 pg/cigarette.
The total nicotine in sidestream smoke is
3.0 mg/cigarette (34). Therefore, the smoker,
by inhaling 100 pg of 3,000 pg, breathes
3.3% ofsidestream nicotine. Accordingly, we
estimated that the smoker inhales 3.3% ofthe
benzene in sidestream smoke. By including
100% ofthe mainstream smoke and 3.3% of
the sidestream smoke, we estimated that each
cigarette delivers 61.5 pg benzene [45 +
(0.033 x 500)]. At 20 cigarettes/day (light
smoker), the inhaled dose is 1,230 pg ben-
zene/day; at 40 cigarettes/day (heavysmoker),
the inhaled dose is 2,460 pgbenzene/day.
Calulation ofexcess risk due to benzene.
Similar to the ELRdue to smoking, the ben-
zene-induced ELR in smokers (16) is
defined as: ELRbenZene = (cumulative lifetime
risk in smokers) - (cumulative lifetime risk in
smokers with the benzene effect removed).
To obtain cumulative lifetime risks ofdeath
from leukemia without the benzene effect,
we constructed life tables in which leukemia
death rates among smokers for each age
group were divided by 1 + p x dfor linear
models, by 1 + , x d2 for models with a sec-
ond-order term only, and by 1 + P x d+ 02
x d2 for models with both a linear and a sec-
ond-order term. In this way, using the
inverse of our dose-response models, we
obtained the expected death rates and cumu-
lative lifetime risk for a population ofsmok-
ers unexposed to benzene.
Bene-attributablefraction ofsmoking-
induced leukemia deaths. The proportion of
smoking-induced leukemia deaths due to the
benzene in cigarette smoke is denoted the ben-
zene-attributable fraction [AF(benzene)] of
leukemia mortality in smokers. This fraction
was calculated by dividing the benzene-
induced ELRbythesmoking-induced ELR:
AF(benzene) = (ELRbenzene)/(ELR ) smoking
Results
Acute myeloid leukemia. The cumulative
lifetime risk (to 75 years of age) of AML
death in never-smokers was 0.095% for
females and 0.128% for males. The lifetime
risk was lower in heavy smokers than in light
smokers for both males and females: for
females, the lifetime risk was 0.135% in
light smokers and 0.132% in heavy smokers;
for males, the lifetime risk was 0.168% in
light smokers and 0.156% in heavy smokers.
Life table results, showing calculations for
the lifetime risk of AML death in male
never-smokers, are provided in Table 3.
The benzene-associated risks among
smokers for AML alone are shown in Table
4. The AML potencies ranged from 2.0 x
10-3 to 3.4 x 10-3 per cumulative gram ben-
zene for the linear models (95% UCL, 3.4 x
10-3 to 8.2 x 10-3). Using maximum likeli-
hood estimates for the linear models, the pro-
portion of smoking-induced AML deaths
attributable to the benzene in cigarette smoke
was estimated to range from 15 to 46% using
potencies that we derived from the Hayes et
al. (24) results (Equation 2); from 19 to 58%
using the potencies published by Crump (22)
[based on the Pliofilm cohort data (23)]; and
from 12 to 36% using our own potency esti-
mates based on the published Pliofilm cohort
results (Equation 1). Based on 95% UCL
potencies ofthese linear models, the AF(ben-
zene) ranged from 19 to 121%.
The potency for the second-order model
(Equation 3) of the Pliofilm data (assuming
one death in the lowest exposure group) was
3.9 x 10-7 per cumulative gram squared
(95% UCL, 7.8 x 10-7), and resulted in
AF(benzene) ranging from 0.05 to 0.29%
(95% UCL, 0.08-0.62%). Equation 4, with
unconstrained parameters, produced a nega-
tive maximum likelihood estimate forPI.
We conducted sensitivity analyses (male
light smokers only) under different assump-
tions regarding the histologic type of the
untyped leukemia deaths in the Pliofilm
cohort. For the linear dose-response model
(Equation 1) with two AML deaths in the
lowest exposure category (1 = 5.9 x 10-4 per
gram), the benzene-attributable fraction was
4.3% (95% UCL, 16%). Using the second-
order model (Equation 3), with zero ( = 2.8
x 10-6 per gram squared) or two ( = 1.9 x
10-7 per gram squared) AML deaths, the
benzene-attributable fractions were 0.40%
(95% UCL, 2.7%) and 0.03% (95% UCL,
0.05%), respectively.
Totalleukemia. The cumulative lifetime
risk (to 75 years of age) of death from any
Environmental Health Perspectives * Volume 108, Number 4, April 2000 335Articles * Korte et al.
type of leukemia in never-smokers was
0.300% for females and 0.421% for males.
For females, the lifetime risks in light and
heavy smokers were 0.344 and 0.379%,
respectively; for males, lifetime risks were
0.451 and 0.474%, respectively.
Results for all leukemia are shown in
Table 5. The leukemia potencies ranged
from 6.6 x 104 to 1.7 x 10-3 per cumulative
gram benzene for the linear models (95%
UCL, 1.6 x 10-3 to 2.4 x 10-3). Using maxi-
mum likelihood potency estimates for the
linear models, the AF(benzene) ofsmoking-
induced leukemia deaths was estimated to
range from 21 to 48% using the potencies
that we estimated from the China cohort
results; from 17 to 39% using potencies
published by Crump based on the Pliofilm
cohort data (22); and from 8 to 19% using
potencies that we estimated from the
Pliofilm cohort. Based on 95% UCL poten-
cies, the attributable fractions ranged from
20 to 66%.
For analyses of the Pliofilm cohort data
based on Equation 3 (second-order term
only), we estimated that the potency was 1.0
x 10-7 per cumulative gram benzene squared
(95% UCL, 2.7 x 10- ), and that the attrib-
utable fractions ranged from 0.02 to 0.11%
(95% UCL, 0.07-0.32%). For analyses
based on Equation 4 (linear and second-
order terms), we estimated the coefficients
for PI and I2 to be 6.2 x 10-4 per gram
(95% UCL, 2.8 x 10-3) and 7.6 x 10- per
gram squared (95% UCL, 3.9 x 10-7),
respectively. The attributable fractions
ranged from 8 to 18% of smoking-related
leukemia; the fractions ranged from 35 to
76% when using UCL potency estimates.
Discussion
In this investigation, we estimated the
contribution of benzene in cigarettes to
excess leukemia mortality observed among
smokers. At an estimated dose of 61.5 pg
benzene/cigarette, the calculated potency
based on the assumption of a second-order
dose-response curve was too low to explain
even 1% of smoking-induced leukemia or
AML. As expected, linear models resulted in
much higher attributable fractions; however,
linear models did not result in implausibly
high attributable fractions (e.g., > 100%),
with the single exception of the UCL for
AML among male heavy smokers, using the
Pliofilm cohort data. The dose-response
model including both linear and quadratic
terms resulted in predictions comparable to
those based on the linear model, at benzene
doses inhaled bysmokers.
Other known or suspected leukemogens
are present in cigarette smoke, including ure-
thane (30,35), 1,3-butadiene (32,36),
radioactive elements (37,38), N-nitrosodi-n-
butylamine (30,39), and styrene (30,40);
benzene is therefore unlikely to be indepen-
dently responsible for all smoking-induced
leukemia. However, based on current knowl-
edge of the leukemogenicity of these
compounds and their relative concentrations
in tobacco smoke, it seems likely that ben-
zene's contribution is substantial. Thus, in
this analysis, dose-response models including
alinear term resulted in much more plausible
AF(benzene) than the model including a sec-
ond-order term only.
As in all risk assessments, we made
assumptions when necessary. First, we
assumed that the potency ofbenzene inhaled
in the occupational setting is equivalent,
gram for gram, to the potency of benzene
vapor emitted from combusted cigarettes. In
both situations, the route of exposure is by
inhalation. As air travels into the lung, rapid
increases in the cross-sectional area result in
a slowing of the air velocity; in addition,
rapid increases in the total surface area ofthe
airwaywalls contribute to extremely efficient
heat exchange. The temperature of cigarette
smoke therefore decreases rapidly to body
temperature once it is inhaled, and potency
differences due to temperature are unlikely
in these two exposure settings. It is possible,
however, that the carcinogenic potency of
benzene exposure in the industrial workplace
differs from the potency ofbenzene in com-
plex mixed exposures such as cigarette
smoke. The overall effect ofthese numerous
coexposures, some of which may provide
potentiating or inhibiting effects on ben-
zene, is difficult to predict. In addition, it
may be impossible with current methods to
determine any benzene potency difference
between these exposure scenarios because of
the low exposure levels experienced by
smokers and the complexity of the cigarette
smoke mixture.
Our second assumption reflects our
choice of multiplicative models for potency
calculations. These models assume that the
effect of a carcinogen is dependent on the
background rate ofthe disease and are appro-
priate when a carcinogen operates on the
same pathway or pathways that produce the
background cancer rate (41). Although
researchers have found that benzene-induced
leukemia is often preceded by benzene-
induced pancytopenia (1(), the mechanism of
benzene-induced leukemia (42) is insuffi-
ciently understood to support a causal path-
way distinct from the significant background
rate ofleukemia. The additive models fit by
Crump (22) would have produced somewhat
lower risk estimates for benzene-induced
leukemia and therefore a smaller contribution
to smoking-induced leukemia. Our final con-
clusions, however, would not have been sub-
stantially altered, i.e., that linear models give
rise to plausible riskestimates.
A third assumption in our extrapolation
of potencies from the occupational cohorts
was that the studies were substantially free of
confounding, misclassification, and other
biases. The Pliofilm cohort is well suited to
minimize the possible confounding effects of
Table 3. Example of life table results: male never-smoker, AML.
P(survival to next
age interval)a
0.94482
0.99872
0.99842
0.99366
0.99169
0.99077
0.98885
0.98956
0.98732
0.98708
0.97985
0.95877
0.93404
0.89991
0.84679
Cumulative
P(survival to
beginning ofinterval)
1.00000
0.94482
0.94361
0.94212
0.93615
0.92837
0.91980
0.90955
0.90005
0.88864
0.87717
0.85949
0.82406
0.76970
0.69266
AML death
rate per 100,000
0.937
0.204
0.206
0.429
0.488
0.596
0.682
0.637
0.750
1.026
1.646
3.098
3.983
7.526
11.667
P(AML death during
interval) given survival to Unconditional P(AML
beginning of interval death during interval)
0.00004556 0.00004556
0.00001021 0.00000965
0.00001031 0.00000972
0.00002138 0.00002015
0.00002437 0.00002282
0.00002978 0.00002765
0.00003402 0.00003129
0.00003167 0.00002880
0.00003724 0.00003352
0.00005095 0.00004528
0.00008145 0.00007144
0.00015169 0.00013038
0.00019250 0.00015863
0.00035715 0.00027490
0.00053744 0.00037226
&Probability of survival is equal to e-' where r= death rate and t= time.
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5-year
age group
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
All-cause death
rate per 100,000
1,135.2
25.6
31.6
127.2
166.3
184.9
223.4
210.0
255.2
260.0
407.1
842.0
1,364.7
2,109.2
3,326.1
Cumulative
P(AML death)
0.0000456
0.0000552
0.0000649
0.0000851
0.0001079
0.0001355
0.0001668
0.0001956
0.0002292
0.0002744
0.0003459
0.0004762
0.0006349
0.0009098
0.0012820
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other leukemogens because the industrial
process did not involve exposure to other
potential carcinogens. Most benzene-exposed
workers in the China cohort were also
exposed to toluene and xylene. These com-
pounds are not established human carcino-
gens, although by competing for P450 they
may reduce the metabolism rate ofbenzene,
resulting in an underestimation of the ben-
zene potency. Possible bias due to the
healthy worker effect has been controlled in
our potency calculations for both cohorts:
our model for the Pliofilm data adjusted for
differences in background rates between
workers and the general population, and the
China results were based on a comparison
with unexposed workers.
In this study, we conducted a sensitivity
analysis ofthe relationship between benzene
and AML under different assumptions
regarding the untyped leukemia cases in the
lowest exposure category presented by
Crump (22). Although Crump indicates no
confirmed cases in the lowest exposure cate-
gory (< 45 ppm-years), a separate analysis of
the Pliofilm cohort by Wong (11) indicated
the presence ofoneAML death in the lowest
exposure category (< 40 ppm-years benzene
exposure). This apparent contradiction is
likely explained by the fact that Crump pre-
sented results based on the Paustenbach et
al. (29) exposure matrix, whereas Wong (11)
presented results based on the Rinsky et al.
(43) exposure matrix.
With regard to thevalidity ofour results,
our linear multiplicative model potencies
based on the Pliofilm cohort are somewhat
smaller than those ofCrump. There are sev-
eral possible reasons for the differences.
Crump used individual data in his analysis,
whereas we calculated potencies based on
published summary data from the cohort.
Crump evaluated several possible lag times
between exposure and the development of
leukemia; we used the potency that he
obtained based on a 5-year lag, but the sum-
mary data that were available for our analysis
did not incorporate lag times. Finally, we
adjusted for the differences in expected mor-
tality between workers and the general
population; Crump did not find the a term
to be statistically significant and excluded it
from his final models.
As noted in "Results," the lifetime risk of
AML mortality is slightly higher in light
smokers than in heavy smokers. This coun-
terintuitive finding reflects the increased risk
to heavy smokers of death from competing
causes, such as other cancers and heart dis-
ease. Although the AML death rates for each
age category are higher for heavy smokers
than for light smokers, the lifetime cumula-
tive risk rises less in the later age categories
among heavy smokers because of their dra-
matically higher all-cause death rate. This
effect is also observed in our results for all
leukemia; however, the cross-over occurs too
late to be reflected in a reversal ofthe lifetime
cumulative probabilities ofleukemia death.
Another issue is the potential for sex dif-
ferences in benzene leukemogenicity. In our
study, we assumed the same potency for
males as for females. Nevertheless, the differ-
ence in overall and smoking-induced rates of
leukemia led to a lower attributable fraction
for females as compared to males.
Background rates ofleukemia are higher for
men than for women. Evidence supporting a
sex difference in benzene leukemogenicity
includes recent results ofphysiologicallybased
pharmacokinetic modeling, which show that
under the same exposure conditions, women
Table 4. Percent of smoking-induced AML deaths attributable to benzene in cigarette smoke, with 95%
UCL.
20 cigarettes/day 40 cigarettes/day
Modela Cohort Potencyb(UCL) Male Female Male Female
Linear China (22X 2.6 x 10-3(3.4 x 10-3) 18.4(23.5) 14.7 (18.8) 45.9(57.9) 29.3(37.1)
Linearc Pliofilm (201 3.4 x 10-3(5.8 x 10-3) 23.6 (38.9) 18.9(31.1) 58.1 (92.4) 37.1(59.1)
Linear PliofilmZ20 2.0 x 10-3 (8.2 x 10-3) 14.4(52.4) 11.5(42.0) 36.2(120.7) 23.2(77.3)
Quadratic Pliofilm (20) 3.9 x 10-7 (7.8 x 10-7) 0.05(0.10) 0.05(0.08) 0.29(0.62) 0.19 (0.38)
"All models are multiplicative (see text). bCarcinogenic potency per cumulative gram, or, for quadratic model, per cumu-
lative gram squared. CPotency published by Crump (20).
Table 5. Percent of smoking-induced leukemia deaths attributable to benzene in cigarette smoke, with
95% UCL.
20 cigarettes/day 40 cigarettes/day
Model8 Cohort Potencyb UCLl Male Female Male Female
Linear China (22) 1.7 x 10-3(2.4 x 10-3) 41.0(57.2) 21.4(29.8) 47.6(65.5) 25.4(34.9)
Linearc Pliofilm (20) 1.4 x 10-3(2.3 x 10-3) 33.1 (55.1) 17.3 (28.7) 38.6(63.3) 20.6(33.7)
Linear Pliofilm (201 6.6 x 10-4(1.6 x 10-3) 16.1(38.4) 8.4(20.0) 19.0(44.6) 10.1(23.8)
Linear + Pliofilm (201 0 = 6.2 x 10-4(2.8 x 10-3) 15.2 (66.6) 7.9 (34.7) 18.0(76.0) 9.6 (40.5)
Quadratic l2 = 7.6 x 10-9(3.9 x 10-7)
Quadratic Pliofilm(20) 1.0x 10-7 (2.7 x 10-7) 0.07 (0.13) 0.02 (0.07) 0.11 (0.32) 0.06 (0.16)
&All models are multiplicative (see text). bCarcinogenic potency per cumulative gram; excepting 12(potency per cumula-
tive gram squared). cPotency published by Crump (20).
may metabolize more benzene than men
despite lower benzene blood concentrations
(44). However, other recent data show that
levels ofprotein adducts formed by benzene
metabolites do not differby sex (45).
In the construction of life tables for
AML and for all leukemia, we were unable
to locate age-specific RRs for former, light,
and heavy smokers. Therefore, for each
smoking category we used the overall smok-
ing RR obtained from Cancer Prevention
Studies I and 11(2). The use ofthe same RR
for all groups from 35 to 74 years of age is
unlikely to cause substantial bias. For lung
cancer, in comparison, RRs derived from
Kahn (21) and Doll and Peto (46) for light
smokers vary only between 6.8 and 9.4
across age groups-a variation of< 50%.
In our life tables, we used U.S. popula-
tion data for smoking prevalence from
September 1989 (20) and for vital statistics
mortality rates (17) from 1990. The latency
period for benzene-induced leukemia is typi-
cally < 10 years (10), although it may be
> 40 years (26); therefore, the cigarettes of
interest in our analysis are those smoked
between 1950 and 1990. A fairly wide range
has been reported for the quantity of ben-
zene in mainstream smoke: 8.0-73.4 pg,
according to the type ofcigarette (low-tar fil-
ter or nonfilter) (32). Ifthe average benzene
content of cigarette smoke, either main-
stream or sidestream, was higher than we
assumed, then we underestimated the
proportion of smoking-induced leukemia
attributable to benzene. Conversely, if the
benzene content of cigarettes has increased
over time, or ifwe overestimated the propor-
tion ofsidestream smoke inhaled by a smok-
er, then we overestimated the contribution
of benzene to leukemia in smokers. In fact,
3.3% ofsidestream could be a maximum. If
the true contribution from sidestream smoke
is closer to zero, our attributable fractions
should be reduced approximately 25%.
Violations of these assumptions are
unlikely to have a major impact on our
results. A significantly more influential
assumption is the shape ofthe dose-response
curve at low exposures. Several authors have
argued that the dose-response curve ofben-
zene in particular must be sublinear (10,47),
with the implication that linear models
result in substantial overestimation of the
low-dose carcinogenic potency. The carcino-
genic potency and the dose-response curve
of benzene have been the subject of both
extensive discussion in the literature and
controversy among policy makers. In 1978,
the Occupational Safety and Health
Administration reduced the permissible 8-hr
workplace exposure from 10 to 1 ppm (48);
this decision was overturned by the U.S.
Supreme Court in 1980 (49). A more
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detailed quantitative risk assessment was
subsequently conducted, and the 1 ppm
standard was reinstated in 1987 (48). That
risk assessment utilized the default assump-
tion (50) oflinearity for low-dose quantita-
tive risk assessment. The argument for this
default is the goal ofachievinghealth protec-
tion; the implicit assumption is that most
curves are sublinear, and that linearity pro-
vides an upper limit ofcarcinogenic potency.
Researchers have established DNA
adduct formation by benzene metabolites
(51-55). It is not yet clear which metabo-
lite(s) ofbenzene are involved in leukemoge-
nesis, although some evidence suggests that
hydroquinone may be important in DNA
adduct formation (56). Benzene and its phe-
nolic metabolites are less active than many
other chemical carcinogens in binding to
DNA (57); nevertheless, recent studies
showed DNA adducts persisting up to 21
days after the administration of benzene
(51). This DNA damage, resulting from a
chemical reaction with a carcinogen, may
initiate cell transformation leading to car-
cinogenesis at any level ofexposure. Proofof
DNA adduct formation after exposure to
benzene therefore provides evidence against
a threshold effect, and would tend to sup-
port the use ofa linearextrapolation model.
In our risk assessment, the range of
extrapolation from the cumulative occu-
pational benzene exposure down to the
cumulative exposure of smokers is approxi-
mately 1 order of magnitude for the China
cohort and approximately 2 orders ofmagni-
tude for the Pliofilm cohort. A light smoker
(20 cigarettes/day) inhales approximately
0.45 g benzene/year, whereas a heavy smoker
(40 cigarettes/day) inhales approximately 0.9
g benzene/year. The lifetime cumulative
exposure to benzene from smoking is there-
fore approximately 3 ppm-years (i.e., work-
years) for a light smoker and 6 ppm-years for
a heavy smoker. An industrial worker
exposed to the current standard of 1 ppm
benzene in air inhales approximately 8 g ben-
zene/year. The smaller range ofextrapolation
from exposure in the China cohort, com-
bined with the substantially larger number of
leukemia deaths and person-years, suggests
that more weight might reasonably be placed
on the findings from this cohort. With
attributable fractions based on linear models
ranging from 21 to 66% for total leukemia,
these results from the China cohort do not
suggest that the shape of the dose-response
curve in this range is sublinear. However, if
the comparison ofour potencies to those of
Crump are informative, it is possible that
our use of published data rather than an
analysis ofthe original data from the China
cohort could have resulted in underestimates
ofattributable fractions.
Notably, the linear-quadratic dose-
response model yielded results similar to
those based on the linear model. At the low
doses ofbenzene inhaled by smokers, the lin-
ear term in the model is more influential
than the second-order term, providing simi-
larly plausible estimates ofthe proportion of
smoking-induced leukemia deaths attribut-
able to the benzene in cigarette smoke. The
dose-response model including a second-
order term only, however, resulted in implau-
sibly low estimates ofbenzene's contribution
to smoking-induced leukemia andAML.
The present analysis provides little evi-
dence for exclusion of linear terms in
extrapolation models: the linear models
extrapolated across 1-2 orders ofmagnitude
ofexposure did not predict implausibly high
proportions ofsmoking-related leukemia, or
smoking-related AML, attributable to the
benzene in cigarettes. Rather, under the
default assumptions, benzene appears to be
responsible for approximately one-tenth to
one-half of smoking-induced leukemia and
up to three-fifths ofsmoking-induced AML.
A more direct determination of the role of
benzene in inducing smoking-related
leukemia may be possible in future studies
through comparisons of the genetic charac-
teristics of leukemia cases in smokers and
nonsmokers. Previous research has identified
several chromosomal aberrations and other
genetic damage in humans and animals
exposed to benzene (51,56-59). Future
research may therefore identify benzene-
specific markers that will allow a direct
assessment of the proportion of leukemias
attributable to benzene exposure among
smokers and nonsmokers.
The attributable fractions calculated in
our study, however, seem reasonable and not
unrealistically high in light ofthe other recog-
nized or suspected leukemogenic compounds
present in cigarette smoke (including ure-
thane, 1,3-butadiene, radioactive elements,
N-nitrosodi-n-butylamine, and styrene).
These additional leukemogens may provide
synergistic effects as well as independent con-
tributions to smoking-related leukemia
mortality. In addition, as-yet unidentified
leukemogens, or potentiation by nonleuke-
mogens, may be important in explaining
smoking-induced leukemia. Nevertheless, the
results presented here for benzene alone pro-
vide evidence supporting the use of linear
models to extrapolate substantially below
occupational exposures. This conclusion is
bolstered by evidence ofDNA adduct forma-
tion bybenzene metabolites (51-55).
Although we provided UCLs in this
paper, U.S. regulatory agencies do not use
them when extrapolating from epidemiologic
data. The use ofmaximum likelihood poten-
cy estimates may limit the margin ofsafety.
In conclusion, we estimate that benzene
is responsible for 8-48% of smoking-
induced leukemia and for 12-58% of
smoking-induced AML. The use of cancer
mortality data for smokers and never-smok-
ers provides a real-world upper bound for
the estimated low-dose carcinogenicity of
cigarette smoke constituents and permits an
empirical check on the plausibility of risks
extrapolated from benzene exposures in
industrial settings 10- to 100-fold higher.
Our findings show that models with linear
terms produce estimates consistent with
known smoking-induced risks and with the
presence ofother leukemogens in mainstream
andsidestream smoke.
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